ACIP Cautions against Use of Seasonal Flu Vaccine in Children


The ACIP has recommended that Afluria, a seasonal flu vaccine, not be given routinely to children younger than 9 years

The CDC’s Advisory Committee on Immunization Practices (ACIP) has recommended that Afluria not be given routinely to children younger than age 9 years. The drug, a trivalent inactivated season flu vaccine, is manufactured by the Australian company CSL Ltd., and distributed in the US by Merck and Co. Inc.

The ACIP based its decision on data that indicate an increased risk of febrile seizures in children ages 6 months through 4 years following vaccination with CSL’s Fluvax and Fluvax Junior, according to a press release. The committee also looked at data that showed a higher incidence of reported fever in children ages 5 years through 8 years following Fluvax vaccination this year compared with the incidence seen after Fluvax vaccination during previous seasons and after immunization with other flu vaccines on the market this year.

A higher incidence of fever in children in that age group also was reported during a 2009 US trial of Afluria, which is antigenically similar to Fluvax and Fluvax Junior. Use of Fluvax and Fluvax Junior was suspended in both Australia and New Zealand earlier this year, according to the committee.

The ACIP recommended that other age-appropriate, licensed seasonal influenza vaccine formulations be used to prevent influenza in children ages 6 months through 8 years. If no other age-appropriate, licensed flu vaccine is available for a child age 5 years through 8 years who has a medical condition that increases his or her risk for influenza complications, the committee said Afluria may be given. However, physicians should discuss the benefits and risks of vaccination with the child's parents or caregivers before administering Afluria.

Four other seasonal vaccines are licensed for use in children in the United States:

  • Sanofi Pasteur’s trivalent inactivated vaccine (marketed as Fluzone) may be used in children ages 6 months and older;
  • MedImmune’s live, attenuated influenza vaccine (marketed as FluMist) may be used in children ages 2 years and older;
  • GlaxoSmithKline’s trivalent inactivated vaccine (marketed as Fluarix) may be used in children ages 3 years and older; and
  • Novartis’ trivalent inactivated vaccine (marketed as Fluvirin) may be used in children ages 4 years and older.

The FDA approved Afluria for use in adults ages 18 and older in 2007, and the vaccine was approved for use in children as young as age 6 months in 2009. Alfluria still is recommended for use in individuals ages 9 years and older.

Related Videos
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Cedric Rutland, MD: Exploring Immunology's Role in Molecule Development
Cedric Rutland, MD: Mechanisms Behind Immunology, Cellular Communication
Glenn S. Tillotson, PhD: Treating Immunocompromised Patients With RBX2660
Paul Feuerstadt, MD: Administering RBX2660 With a Colonoscopy
Jessica Allegretti, MD, MPH: Evaluating the First Few Months of RBX2660
© 2024 MJH Life Sciences

All rights reserved.